Last reviewed · How we verify

Juvenile rheumatoid arthritis — Treatment Landscape & Competitive Intelligence

Juvenile rheumatoid arthritis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Juvenile rheumatoid arthritis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Roactemra tocilizumab Roche Interleukin-6 Receptor Antagonist [EPC] Interleukin-6 receptor 2010-01-01
Mobic MELOXICAM Boehringer Ingelheim Nonsteroidal Anti-inflammatory Drug [EPC] Prostaglandin G/H synthase 2 2000-01-01
Celebrex celecoxib Pfizer Inc. (originally Searle/Pharmacia) Nonsteroidal Anti-inflammatory Drug [EPC] COX-2 1998-12-31
Daypro Oxaprozin Solubiomix Nonsteroidal Anti-inflammatory Drug [EPC] Prostaglandin G/H synthase 1 1992-01-01
Lodine ETODOLAC Pfizer Nonsteroidal Anti-inflammatory Drug [EPC] Prostaglandin G/H synthase 2 1991-01-01
Aleve naproxen Generic (originally Syntex) NSAID Aldo-keto reductase family 1 member C2, Aldo-keto reductase family 1 member C3, Prostaglandin G/H synthase 1 1976-01-01
Lithobid lithium carbonate Generic (multiple manufacturers) Mood stabilizer Inositol-1(or 4)-monophosphatase 1, Glycogen synthase kinase-3 1970-04-06
Advil ibuprofen Generic (originally Boots Group) Nonsteroidal Anti-inflammatory Drug [EPC] Sodium-coupled monocarboxylate transporter 1, Acid-sensing ion channel 1, Aldo-keto reductase family 1 member C2 1969-01-15
Medrol methylprednisolone Generic (originally Upjohn/Pfizer) Glucocorticoid (corticosteroid) Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor 1957-10-01
Deltasone prednisone Generic (originally Schering) Corticosteroid [EPC] Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor 1955-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 8 drugs in Juvenile rheumatoid arthritis
  2. Pfizer · 3 drugs in Juvenile rheumatoid arthritis
  3. Generic (originally Schering) · 2 drugs in Juvenile rheumatoid arthritis
  4. Generic (multiple manufacturers) · 1 drug in Juvenile rheumatoid arthritis
  5. Generic (originally Boots Group) · 1 drug in Juvenile rheumatoid arthritis
  6. Generic (originally Lederle Laboratories) · 1 drug in Juvenile rheumatoid arthritis
  7. Generic (originally Syntex) · 1 drug in Juvenile rheumatoid arthritis
  8. Generic (originally Upjohn/Pfizer) · 1 drug in Juvenile rheumatoid arthritis
  9. Hannover Medical School · 1 drug in Juvenile rheumatoid arthritis
  10. Leiden University Medical Center · 1 drug in Juvenile rheumatoid arthritis
  11. M.D. Anderson Cancer Center · 1 drug in Juvenile rheumatoid arthritis
  12. POZEN · 1 drug in Juvenile rheumatoid arthritis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Juvenile rheumatoid arthritis:

Cite this brief

Drug Landscape (2026). Juvenile rheumatoid arthritis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/juvenile-rheumatoid-arthritis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing